Welcure Drugs & Pharmaceuticals Limited EBIT

The latest EBIT for WELCURE.BO is $-74M as of March 2026. That compares with $30M in the prior-year period — down 343.7% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Welcure Drugs & Pharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, WELCURE.BO's EBIT moved from $30M to $-74M — a 343.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Welcure Drugs & Pharmaceuticals Limited's operating scale or balance-sheet position.

Against its sector companies, WELCURE.BO currently prints $-74M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Welcure Drugs & Pharmaceuticals Limited's growth, margins, and balance sheet.

A EBIT figure of $-74M for WELCURE.BO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting WELCURE.BO's EBIT ($-74M), review year-over-year change from $30M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.